PMID- 15788977
OWN - NLM
STAT- MEDLINE
DCOM- 20050414
LR  - 20181201
IS  - 0026-4725 (Print)
IS  - 0026-4725 (Linking)
VI  - 53
IP  - 1
DP  - 2005 Feb
TI  - Optimal antithrombotic treatment for percutaneous coronary intervention.
PG  - 15-42
AB  - Recent years have witnessed significant advances in the percutaneous treatment of 
      patients with atherosclerotic vascular disease. Anti-platelet and anti-thrombotic 
      agents are routinely administered to minimize the risk of peri-procedural 
      myonecrosis, stent thrombosis and other procedural complications. This article 
      presents a current view of optimal adjunctive antithrombotic therapy for 
      percutaneous coronary interventions (PCI), recognizing that optimal is a 
      necessarily subjective label. This article focuses specifically on anticoagulant 
      agents such as unfractionated heparin (UFH), the low-molecular weight heparins 
      (LMWH), and direct thrombin inhibitors, and antiplatelet agents, such as aspirin, 
      thienopyridines, and glycoprotein IIb/IIIa antagonists. It starts with a general 
      discussion of anticoagulation and percutaneous intervention, followed by a 
      summary of the modern-day view of the coagulation process. The mechanism of 
      action of the individual agents is then presented, followed by some of the 
      evidence base of recent clinical trials of anticoagulant and antiplatelet agents 
      in PCI. Finally, we present summary recommendations for procedural 
      anticoagulation in low risk, not-low risk, and high risk PCI, and list what we 
      feel are appropriate doses for the agents employed. Ultimately, though, it is the 
      individual interventional cardiologists who must decide for themselves exactly 
      what constitutes optimal antithrombotic therapy for PCI.
FAU - Kadakia, R A
AU  - Kadakia RA
AD  - Texas Heart Institute, St. Luke's Episcopal Hospital, Baylor College of Medicine, 
      The University of Texas Health Science Center at Houston, Houston, TX, USA.
FAU - Ferguson, J J
AU  - Ferguson JJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Minerva Cardioangiol
JT  - Minerva cardioangiologica
JID - 0400725
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
RN  - A74586SNO7 (Clopidogrel)
RN  - EC 3.4.21.5 (Thrombin)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Angioplasty, Balloon, Coronary/adverse effects/methods
MH  - Anticoagulants/*pharmacology/*therapeutic use
MH  - Aspirin/pharmacology/therapeutic use
MH  - Blood Coagulation/*drug effects
MH  - Clinical Trials as Topic
MH  - Clopidogrel
MH  - Heparin, Low-Molecular-Weight/pharmacology/therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Pyridines/pharmacology/therapeutic use
MH  - Stents/adverse effects
MH  - Thrombin/antagonists & inhibitors
MH  - Thrombosis/etiology/*prevention & control
MH  - Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Treatment Outcome
RF  - 122
EDAT- 2005/03/25 09:00
MHDA- 2005/04/15 09:00
CRDT- 2005/03/25 09:00
PHST- 2005/03/25 09:00 [pubmed]
PHST- 2005/04/15 09:00 [medline]
PHST- 2005/03/25 09:00 [entrez]
PST - ppublish
SO  - Minerva Cardioangiol. 2005 Feb;53(1):15-42.